Rocket Pharmaceuticals Inc Total Assets
Rocket Pharmaceuticals Inc total assets. Based on the latest financial reports, Rocket Pharmaceuticals Inc (RCKT) holds total assets worth $423.10 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see RCKT company net worth for the company's overall valuation and market capitalisation.
Total Assets of Rocket Pharmaceuticals Inc (2012–2025)
Total assets of Rocket Pharmaceuticals Inc from 2012 to 2025. This chart illustrates how Rocket Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data. See RCKT share price today for real-time trading data and today's change.
Rocket Pharmaceuticals Inc - Asset Composition Analysis
Rocket Pharmaceuticals Inc Total Assets Breakdown (December 2025)
Rocket Pharmaceuticals Inc total assets breakdown as of December 2025. Rocket Pharmaceuticals Inc's total assets of $423.10 Million consist of 58.3% current assets and 41.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 23.5% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $25.15 Million | 7.6% |
| Goodwill | $39.15 Million | 11.9% |
Asset Composition Trend (2012–2025)
This chart illustrates how Rocket Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore RCKT current assets to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Rocket Pharmaceuticals Inc's current assets represent 58.3% of total assets in 2025, a decrease from 99.7% in 2012.
- Cash Position: Cash and equivalents constituted 23.5% of total assets in 2025, down from 96.6% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 18.0% of total assets, an increase from 0.0% in 2012.
- Asset Diversification: The largest asset category is goodwill at 11.9% of total assets.
Rocket Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Rocket Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Rocket Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 9.24 | 6.39 | 17.36 |
| Quick Ratio | 9.24 | 6.39 | 17.36 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $258.23 Million | $233.76 Million | $400.58 Million |
Rocket Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Rocket Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.15 |
| Latest Market Cap to Assets Ratio | 0.83 |
| Asset Growth Rate (YoY) | -37.4% |
| Total Assets | $330.45 Million |
| Market Capitalization | $275.53 Million USD |
Valuation Analysis
Near Book Valuation: The market values Rocket Pharmaceuticals Inc's assets close to their book value (0.83x), suggesting investors view the company's assets at approximately fair value.
Significant Asset Reduction: Rocket Pharmaceuticals Inc's assets decreased by 37.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Rocket Pharmaceuticals Inc (2012–2025)
The table below shows the annual total assets of Rocket Pharmaceuticals Inc from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $330.45 Million | -37.38% |
| 2024-12-31 | $527.70 Million | -6.82% |
| 2023-12-31 | $566.34 Million | +2.63% |
| 2022-12-31 | $551.81 Million | +11.02% |
| 2021-12-31 | $497.02 Million | -15.88% |
| 2020-12-31 | $590.82 Million | +58.77% |
| 2019-12-31 | $372.12 Million | +48.07% |
| 2018-12-31 | $251.31 Million | +146.92% |
| 2017-12-31 | $101.78 Million | -21.50% |
| 2016-12-31 | $129.65 Million | +14.41% |
| 2015-12-31 | $113.32 Million | +1952.92% |
| 2014-12-31 | $5.52 Million | -57.09% |
| 2013-12-31 | $12.86 Million | +805.21% |
| 2012-12-31 | $1.42 Million | -- |
About Rocket Pharmaceuticals Inc
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States. It develops in vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading … Read more